{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "marketState": "PRE", "messageBoardId": "finmb_225998297", "regularMarketChangePercent": -0.10433145, "regularMarketPrice": 0.383, "exchange": "NGM", "shortName": "Allarity Therapeutics, Inc.", "longName": "Allarity Therapeutics, Inc.", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1640097000000, "priceHint": 4, "preMarketChange": -0.0029999912, "preMarketChangePercent": -0.7832875, "preMarketTime": 1684228834, "preMarketPrice": 0.38, "regularMarketChange": -0.00040000677, "regularMarketTime": 1684180800, "regularMarketDayHigh": 0.39, "regularMarketDayRange": "0.3703 - 0.39", "regularMarketDayLow": 0.3703, "regularMarketVolume": 1031929, "regularMarketPreviousClose": 0.3834, "bid": 0.0, "ask": 0.0, "bidSize": 14, "askSize": 10, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 0.3834, "averageDailyVolume3Month": 3104019, "averageDailyVolume10Day": 3040390, "fiftyTwoWeekLowChange": 0.01999998, "fiftyTwoWeekLowChangePercent": 0.055096366, "fiftyTwoWeekRange": "0.363 - 118.3", "fiftyTwoWeekHighChange": -117.917, "fiftyTwoWeekHighChangePercent": -0.99676245, "fiftyTwoWeekLow": 0.363, "fiftyTwoWeekHigh": 118.3, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -73.42, "epsForward": -19.82, "epsCurrentYear": -30.58, "priceEpsCurrentYear": -0.012524526, "sharesOutstanding": 3849180, "bookValue": -0.249, "fiftyDayAverage": 2.11208, "fiftyDayAverageChange": -1.7290801, "fiftyDayAverageChangePercent": -0.81866217, "twoHundredDayAverage": 17.68607, "twoHundredDayAverageChange": -17.30307, "twoHundredDayAverageChangePercent": -0.97834456, "marketCap": 1553225, "forwardPE": -0.019323915, "priceToBook": -1.5381526, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-12-21", "prevName": "Oncology Venture A/S", "nameChangeDate": "2023-05-15", "averageAnalystRating": "3.0 - Hold", "tradeable": false, "cryptoTradeable": false, "displayName": "Allarity Therapeutics", "symbol": "ALLR"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "24 School Street", "address2": "2nd Floor", "city": "Boston", "state": "MA", "zip": "02108", "country": "United States", "phone": "(401) 426-4664", "website": "https://allarity.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.", "companyOfficers": [{"maxAge": 1, "name": "Mr. James G. Cullem J.D.", "age": 52, "title": "CEO, Chief Bus. Officer, SVP of Corp. Devel., Sec. & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 343410, "fmt": "343.41k", "longFmt": "343,410"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas H. Jensen", "age": 44, "title": "Founder, Sr. VP of Investor Relations & Director", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Joan Y. Brown", "age": 68, "title": "Interim CFO & Director of Financial Reporting", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 180000, "fmt": "180k", "longFmt": "180,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marie  Foegh DrSc, M.D.", "age": 78, "title": "Chief Medical Officer", "yearBorn": 1944, "fiscalYear": 2022, "totalPay": {"raw": 340309, "fmt": "340.31k", "longFmt": "340,309"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.", "age": 67, "title": "Co-Founder", "yearBorn": 1955, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Steen Meier Knudsen Ph.D.", "age": 61, "title": "Founder & Chief Scientific Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Annie  Rasmussen", "age": 65, "title": "Chief of Clinical Operations", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Claus Frisenberg Pedersen", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}